Infinity制药

INFI NASDAQ
1.610
-0.040
-2.42%
盘后: 1.680 +0.07 +4.35% 16:00 07/19 EDT
开盘
1.640
昨收
1.650
最高
1.680
最低
1.610
成交量
2.17万
成交均量(3M)
8.08万
52周最高
2.920
52周最低
1.000
换手率
0.04%
市值
9,165.01万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Infinity制药 INFI股票价格,Infinity制药股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.
展开 >

最近浏览

名称
价格
涨跌幅